NCT00716248

Bucillamine Study of Holding Remission After Infliximab Dose-off

The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Saitama Medical University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

Patients with rheumatoid arthritis who have been well controlled with methotrexate plus infliximab may remain in remission or low disease activity without infliximab. And the chance of sustained remission increase by the addition of another DMARD, bucillamine, at the time of discontinuing infliximab. The BuSHIDO trial is the prospective, randomized, controlled study comparing MTX monotherapy and MTX plus bucillamine combination therapy as to the rate of disease flare after discontinuing infliximab.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	bucillamine	bucillamine 100 mg, twice a day
DRUG	methotrexate	methotrexate 6 mg or more per week

Timeline

• Start date: 2007-01-01
• Primary completion: 2011-12-01
• First posted: 2008-07-16
• Last updated: 2011-01-05

Locations

1 site across 1 country: Japan